Agreement with major biotech

Scancell Signs Agreement with Major International Biotechnology Company to Evaluate an Antibody in the Glymab® Portfolio

Exclusivity has been granted to evaluate anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform.

Scancell Holdings plc (AIM: SCLP), the developer of novel oncology immunotherapies today announces a major international biotechnology company, will exclusively evaluate a Scancell investigational anti-glycan monoclonal antibody for development of novel therapeutic products. Under the terms of the agreement, Scancell has granted the company seven months exclusivity for evaluation, which includes an $1M exclusivity payment payable within 30 days.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "We are very pleased to announce this agreement today with a leading international biotechnology company. This is now the second anti-glycan monoclonal antibody generated via our proprietary GlyMab® platform to be evaluated, the first now being developed under a commercial licence agreement. This provides further validation of the potential of our antibody platform to create novel, differentiated antibody products. Whilst the agreement is for an initial exclusive evaluation period, there is an option to licence, and we look forward to providing the market with any updates in due course."

The Scancell anti-glycan monoclonal antibody is a humanised antibody developed by Scancell, using its novel anti-cancer GlyMab® platform. This is one of five monoclonal antibodies currently in Scancell's antibody portfolio which provides a rich reservoir of potential products for its in-house clinical development and also for further deals.

About GlyMab®

Scancell is building a pipeline of differentiated anti-cancer monoclonal antibodies ('mAbs') that target sugar motifs rather than proteins. The Company currently has five novel mAbs in early-stage development and has the potential to use its unique methodology to identify many more mAbs against glycan targets in the future. All cells are covered by a dense layer of sugar structures, called glycans, which change when a normal cell turns into a cancer cell. These glycan motifs that are associated with tumour malignancies can be targeted by antibodies such as the Company's GlyMab® portfolio. A robust portfolio of patents and applications, as well as know-how, surround the GlyMab® platform and generated drug candidates. The GlyMab® technology is part of Scancell's antibody portfolio, joining AvidiMab®, a technology that can be applied to all antibodies (regardless of the technology used to generate them), enhancing their potency and ability to directly kill tumour cells.